Genotyped Hepatocytes for Polymorphic Enzyme Drug Metabolism Studies
Product News Apr 13, 2016
Geneknown™ hepatocytes are pools of cryopreserved cells from multiple donors assembled to study the effects of specific genetic variants on drug metabolism and transport in human hepatocytes in vitro.
Drug metabolism studies conducted with Geneknown™ pooled human hepatocytes can identify risks of adverse drug interactions present only in genetically-defined subpopulations of patients. Such risks can remain undetected when pooled hepatocytes representing multiple genotypes are utilized.
Thirty pharmacogenetically-relevant genes were evaluated for the presence of significant alleles and SNPs (single nucleotide polymorphisms). A full list of the alleles and SNP IDs comprising the characterization of Geneknown™ hepatocytes can be found on Sekisui XenoTech’s website.
Highlights of Geneknown™ pooled human hepatocytes include:
• Cells were cryopreserved with a patent pending single-freeze process for high viability and cell yield
• CYP2C19*2/*2 no activity homozygotes and CYP2C19*1/*1 wild-type controls
• Complex genetics of CYP2D gene cluster are characterized with 25 individual SNP assays, as well as, CYP2D6 and CYP2D7 gene copy number variation assays, allowing identification of ultra-rapid, extensive and poor metabolizers
• CYP3A5*1/*1 high-activity homozygotes, CYP3A5*1/*3 intermediate activity heterozygotes and CYP3A5*3/*3 no-activity control cells
• UGT1A1 low-activity donors carrying two alleles of reduced activity and wild-type UGT1A1*1/*1 control donors
• OATP1B1*5/*5 homozygotes and wild-type OATP1B1*1/*1 control cells